Otg1 Inhibitors
Chemical inhibitors of Otg1 can affect the protein through various mechanisms by targeting specific signaling pathways and kinases. Staurosporine and Bisindolylmaleimide I, for example, are effective in blocking the phosphorylation processes essential for Otg1 activity. Staurosporine achieves this by broadly targeting protein kinases, which can lead to the inhibition of Otg1 by preventing necessary phosphorylation events. On the other hand, Bisindolylmaleimide I specifically inhibits protein kinase C (PKC), which can suppress Otg1 if PKC-mediated signaling is crucial for its activation or function. LY294002 and Wortmannin are inhibitors that interfere with phosphoinositide 3-kinases (PI3K) signaling pathways. The action of LY294002 and Wortmannin can result in the downregulation of Otg1 by blocking PI3K-dependent pathways, potentially affecting Otg1's role in these routes. Similarly, SP600125 and SB203580 restrict the activity of Otg1 by targeting the c-Jun N-terminal kinase (JNK) and p38 MAP kinase respectively, which could be vital if Otg1's functionality is regulated by either of these signaling molecules.
Additionally, PD98059 and U0126 are chemicals that inhibit MAP kinase kinase (MEK) and consequently the activation of extracellular signal-regulated kinases (ERK). If Otg1 is dependent on the MEK/ERK pathway for its function, the use of PD98059 or U0126 can inhibit Otg1 by disrupting this signaling cascade. PP2, a selective inhibitor of Src family tyrosine kinases, can also inhibit Otg1 by preventing Src kinase activity, assuming Otg1 relies on these kinases. Rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), can inhibit Otg1 by blocking mTOR signaling which may be implicated in Otg1's functional processes. Lastly, Go6983 and Ro-31-8220 target PKC, with Ro-31-8220 also capable of inhibiting protein kinase A (PKA) and protein kinase G (PKG). Inhibition of these kinases by Go6983 or Ro-31-8220 can lead to a decrease in Otg1 activity if it is regulated by any of these kinases. Each chemical inhibitor targets specific kinases or pathways, allowing for the modulation of Otg1 activity through precise molecular interventions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which can inhibit Otg1 by blocking phosphorylation processes that Otg1 may be involved in or depend upon for activation or stabilization. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I, also known as GF 109203X, is a specific inhibitor of protein kinase C (PKC). Otg1, which may require PKC-mediated signaling for its activation or function, can be inhibited by the action of this chemical, which impedes PKC's catalytic activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. It can inhibit Otg1 by disrupting PI3K-dependent signaling pathways which could be essential for Otg1's functional activity, including its regulation or interaction with other molecular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that can inhibit Otg1 by preventing PI3K-mediated signaling, potentially affecting downstream pathways essential for Otg1's function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK can lead to the functional inhibition of Otg1 if Otg1 function is JNK-dependent, either directly or through regulatory mechanisms that control Otg1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. By inhibiting p38 MAP kinase, SB203580 can inhibit Otg1 if Otg1's activity or stability is regulated through the p38 MAPK signaling pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MAP kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERK). By inhibiting MEK, PD98059 can disrupt ERK pathway signaling, which can inhibit Otg1 if its function is associated with ERK signaling regulation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. If Otg1 relies on Src kinase signaling for its activity, PP2 can functionally inhibit Otg1 by blocking the Src kinase activity which is potentially crucial for Otg1 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, and by inhibiting these kinases, it can prevent the activation of the ERK pathway. Otg1 can be functionally inhibited by U0126 if its activity is dependent on signals transmitted through the MEK/ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is a specific inhibitor of mTOR (mammalian target of rapamycin). By inhibiting mTOR signaling, Rapamycin can inhibit Otg1 if Otg1 function is linked to mTOR signaling, such as through regulation of growth or autophagy processes that involve Otg1. | ||||||